Cytokinetics (CYTK) Announces Secondary Analysis From GALACTIC-HF to Be Presented in Late Breaking Clinical Trial Session at ACC.21

March 18, 2021 7:33 AM EDT
Get Alerts CYTK Hot Sheet
Price: $24.16 --0%

Overall Analyst Rating:
    BUY (Down Down)

Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship to patient baseline ejection fraction will be presented in a Late Breaking Clinical Trial session at the American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21) by John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF.

Title: 410-16 Impact Of Ejection Fraction On The Therapeutic Effect Of Omecamtiv Mecarbil In Patients With Heart Failure And Reduced Ejection Fraction: A Secondary Analysis From GALACTIC-HF (Global Approach To Lowering Adverse Cardiac Outcomes Through Improving Contractility In Heart Failure)Presenter: John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HFDate: May 17, 2021Session Title: Late-Breaking Clinical Trials IVSession Time: 8:00 – 9:15 AM ETPresentation Time: 9:00 – 9:10 AM ET



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Related Entities

Twitter, FDA